PTEN: a new guardian of the genome (original) (raw)
Abounader R, Reznik T, Colantuoni C, Martinez-Murillo F, Rosen EM, Laterra J . (2004). Regulation of c-Met-dependent gene expression by PTEN. Oncogene23: 9173–9182. ArticleCASPubMed Google Scholar
Agrawal S, Pilarski R, Eng C . (2005). Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. Hum Mol Genet14: 2459–2468. ArticleCASPubMed Google Scholar
Backman SA, Ghazarian D, So K, Sanchez O, Wagner KU, Hennighausen L et al. (2004). Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci USA101: 1725–1730. ArticleCASPubMedPubMed Central Google Scholar
Backman SA, Stambolic V, Suzuki A, Haight J, Elia A, Pretorius J et al. (2001). Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte–Duclos disease. Nat Genet29: 396–403. ArticleCASPubMed Google Scholar
Bai F, Pei XH, Pandolfi PP, Xiong Y . (2006). p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. Mol Cell Biol26: 4564–4576. ArticleCASPubMedPubMed Central Google Scholar
Bilbao C, Rodriguez G, Ramirez R, Falcon O, Leon L, Chirino R et al. (2006). The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer119: 563–570. ArticleCASPubMed Google Scholar
Bischoff FZ, Strong LC, Yim SO, Pratt DR, Siciliano MJ, Giovanella BC et al. (1991). Tumorigenic transformation of spontaneously immortalized fibroblasts from patients with a familial cancer syndrome. Oncogene6: 183–186. CASPubMed Google Scholar
Cantley LC, Neel BG . (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA96: 4240–4245. ArticleCASPubMedPubMed Central Google Scholar
Chang CJ, Freeman DJ, Wu H . (2004). PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem279: 29841–29848. ArticleCASPubMed Google Scholar
Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H . (2008). PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol28: 3281–3289. ArticleCASPubMedPubMed Central Google Scholar
Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature436: 725–730. ArticleCASPubMedPubMed Central Google Scholar
Chung JH, Ginn-Pease ME, Eng C . (2005). Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res65: 4108–4116. ArticleCASPubMed Google Scholar
Cully M, You H, Levine AJ, Mak TW . (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer6: 184–192. ArticleCASPubMed Google Scholar
Di Cristofano A, Pandolfi PP . (2000). The multiple roles of PTEN in tumor suppression. Cell100: 387–390. ArticleCASPubMed Google Scholar
Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP . (1998). Pten is essential for embryonic development and tumour suppression. Nat Genet19: 348–355. ArticleCASPubMed Google Scholar
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature356: 215–221. ArticleCASPubMed Google Scholar
Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS . (2008). PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci USA105: 2622–2627. ArticleCASPubMedPubMed Central Google Scholar
Eng C, Peacocke M . (1998). PTEN and inherited hamartoma-cancer syndromes. Nat Genet19: 223. ArticleCASPubMed Google Scholar
Fanning AS, Anderson JM . (1999). Protein modules as organizers of membrane structure. Curr Opin Cell Biol11: 432–439. ArticleCASPubMed Google Scholar
Flores-Delgado G, Liu CW, Sposto R, Berndt N . (2007). A limited screen for protein interactions reveals new roles for protein phosphatase 1 in cell cycle control and apoptosis. J Proteome Res6: 1165–1175. ArticleCASPubMed Google Scholar
Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R et al. (2003). PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell3: 117–130. ArticleCASPubMed Google Scholar
Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM et al. (1986). A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature323: 643–646. ArticleCASPubMed Google Scholar
Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P et al. (2000). Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest80: 65–72. ArticleCASPubMed Google Scholar
Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H . (1999). The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA96: 10182–10187. ArticleCASPubMedPubMed Central Google Scholar
Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H . (2000). Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res60: 7033–7038. CASPubMed Google Scholar
Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, Frierson HF et al. (2004). PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene23: 6788–6797. ArticleCASPubMed Google Scholar
Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U et al. (2000). Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol156: 1693–1700. ArticleCASPubMedPubMed Central Google Scholar
Ginn-Pease ME, Eng C . (2003). Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res63: 282–286. CASPubMed Google Scholar
Gu J, Tamura M, Yamada KM . (1998). Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol143: 1375–1383. ArticleCASPubMedPubMed Central Google Scholar
Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL et al. (1994). Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev8: 2939–2952. ArticleCASPubMed Google Scholar
Hong TM, Yang PC, Peck K, Chen JJ, Yang SC, Chen YC et al. (2000). Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am J Respir Cell Mol Biol23: 355–363. ArticleCASPubMed Google Scholar
Iida S, Nakamura Y, Fujii H, Kimura M, Moriwaki K . (1998). A heterozygous germline mutation of the PTEN/MMAC1 gene in a patient with Cowden disease. Int J Mol Med1: 565–568. CASPubMed Google Scholar
Iida S, Ono A, Sayama K, Hamaguchi T, Fujii H, Nakajima H et al. (2000). Accelerated decline of blood glucose after intravenous glucose injection in a patient with Cowden disease having a heterozygous germline mutation of the PTEN/MMAC1 gene. Anticancer Res20: 1901–1904. CASPubMed Google Scholar
Kanaseki T, Torigoe T, Hirohashi Y, Hirai I, Himi T, Sato N . (2002). Identification of germline mutation of PTEN gene and analysis of apoptosis resistance of the lymphocytes in a patient with Cowden disease. Pathobiology70: 34–39. ArticlePubMed Google Scholar
Kang-Park S, Lee YI . (2003). PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett545: 203–208. ArticleCASPubMed Google Scholar
Kang-Park S, Lee YI, Lee YI . (2003). PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett545: 203–208. ArticleCASPubMed Google Scholar
Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV et al. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell71: 587–597. ArticleCASPubMed Google Scholar
Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Kato S et al. (2000). Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res6: 3937–3943. CASPubMed Google Scholar
Kimura T, Suzuki A, Fujita Y, Yomogida K, Lomeli H, Asada N et al. (2003). Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development130: 1691–1700. ArticleCASPubMed Google Scholar
Koul A, Willen R, Bendahl PO, Nilbert M, Borg A . (2002). Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer94: 2369–2379. ArticleCASPubMed Google Scholar
Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SA et al. (2007). PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway. Mol Cell Biochem300: 77–87. ArticleCASPubMed Google Scholar
Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C . (2002). Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet32: 355–357. ArticleCASPubMed Google Scholar
Lachyankar MB, Sultana N, Schonhoff CM, Mitra P, Poluha W, Lambert S et al. (2000). A role for nuclear PTEN in neuronal differentiation. J Neurosci20: 1404–1413. ArticleCASPubMedPubMed Central Google Scholar
Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T et al. (2007). TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res9: R30. ArticlePubMedPubMed CentralCAS Google Scholar
Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y et al. (1999). Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell99: 323–334. ArticleCASPubMed Google Scholar
Leslie NR, Yang X, Downes CP, Weijer CJ . (2007). PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol17: 115–125. ArticleCASPubMedPubMed Central Google Scholar
Levine AJ, Finlay CA, Hinds PW . (2004). P53 is a tumor suppressor gene. Cell116: S67–S69, 61 p following S69. ArticleCASPubMed Google Scholar
Li DM, Sun H . (1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res57: 2124–2129. CASPubMed Google Scholar
Li DM, Sun H . (1998). PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA95: 15406–15411. ArticleCASPubMedPubMed Central Google Scholar
Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N et al. (1998). The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res58: 5667–5672. CASPubMed Google Scholar
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science275: 1943–1947. ArticleCASPubMed Google Scholar
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z et al. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet16: 64–67. ArticleCASPubMed Google Scholar
Liliental J, Moon SY, Lesche R, Mamillapalli R, Li D, Zheng Y et al. (2000). Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol10: 401–404. ArticleCASPubMed Google Scholar
Liu F, Wagner S, Campbell RB, Nickerson JA, Schiffer CA, Ross AH . (2005a). PTEN enters the nucleus by diffusion. J Cell Biochem96: 221–234. ArticleCASPubMed Google Scholar
Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK . (2005b). Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol25: 6211–6224. ArticleCASPubMedPubMed Central Google Scholar
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD . (1992). Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell70: 923–935. ArticleCASPubMed Google Scholar
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T . (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature362: 847–849. ArticleCASPubMed Google Scholar
Maehama T, Dixon JE . (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem273: 13375–13378. ArticleCASPubMed Google Scholar
Mahimainathan L, Choudhury GG . (2004). Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem279: 15258–15268. ArticleCASPubMed Google Scholar
Maier D, Jones G, Li X, Schonthal AH, Gratzl O, Van Meir EG et al. (1999). The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res59: 5479–5482. CASPubMed Google Scholar
Malkin D, Li FP, Strong LC, Fraumeni Jr JF, Nelson CE, Kim DH et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science250: 1233–1238. ArticleCASPubMed Google Scholar
Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H et al. (2001). Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res61: 3741–3749. CASPubMed Google Scholar
Mayo LD, Donner DB . (2002). The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci27: 462–467. ArticleCASPubMed Google Scholar
Mayo MW, Madrid LV, Westerheide SD, Jones DR, Yuan XJ, Baldwin Jr AS et al. (2002). PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem277: 11116–11125. ArticleCASPubMed Google Scholar
McGarrity TJ, Wagner Baker MJ, Ruggiero FM, Thiboutot DM, Hampel H, Zhou XP et al. (2003). GI polyposis and glycogenic acanthosis of the esophagus associated with PTEN mutation positive Cowden syndrome in the absence of cutaneous manifestations. Am J Gastroenterol98: 1429–1434. ArticlePubMed Google Scholar
Medema RH, Herrera RE, Lam F, Weinberg RA . (1995). Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA92: 6289–6293. ArticleCASPubMedPubMed Central Google Scholar
Minaguchi T, Waite KA, Eng C . (2006). Nuclear localization of PTEN is regulated by Ca(2+) through a tyrosil phosphorylation-independent conformational modification in major vault protein. Cancer Res66: 11677–11682. ArticleCASPubMed Google Scholar
Moon SK, Kim HM, Kim CH . (2004). PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-kappaB and AP-1 in vascular smooth muscle cells. Arch Biochem Biophys421: 267–276. ArticleCASPubMed Google Scholar
Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA et al. (1998). The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA95: 13513–13518. ArticleCASPubMedPubMed Central Google Scholar
Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH et al. (1997). P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA94: 9052–9057. ArticleCASPubMedPubMed Central Google Scholar
Nan B, Snabboon T, Unni E, Yuan XJ, Whang YE, Marcelli M . (2003). The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol31: 169–183. ArticleCASPubMed Google Scholar
Okumura K, Zhao M, DePinho RA, Furnari FB, Cavenee WK . (2005). PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle4: 540–542. ArticleCASPubMed Google Scholar
Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, Jorcano JL . (1999). PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene18: 7462–7468. ArticleCASPubMed Google Scholar
Park MJ, Kim MS, Park IC, Kang HS, Yoo H, Park SH et al. (2002). PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87 MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res62: 6318–6322. CASPubMed Google Scholar
Parsons R . (2004). Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol15: 171–176. ArticleCASPubMed Google Scholar
Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA et al. (2000). Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol157: 1097–1103. ArticleCASPubMedPubMed Central Google Scholar
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM et al. (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA96: 1563–1568. ArticleCASPubMedPubMed Central Google Scholar
Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L et al. (2005). Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell7: 193–204. ArticleCASPubMed Google Scholar
Puc J, Parsons R . (2005). PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle4: 927–929. ArticleCASPubMed Google Scholar
Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, Richter KH et al. (1995). Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene11: 635–645. CASPubMed Google Scholar
Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A . (2004). Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science303: 1179–1181. ArticleCASPubMed Google Scholar
Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM et al. (1999). Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA96: 2110–2115. ArticleCASPubMedPubMed Central Google Scholar
Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen M, Staaf J et al. (2008). Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet40: 102–107. ArticleCASPubMed Google Scholar
Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML et al. (1999). Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res59: 1820–1824. CASPubMed Google Scholar
Sansal I, Sellers WR . (2004). The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol22: 2954–2963. ArticleCASPubMed Google Scholar
Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP et al. (2007). Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell128: 157–170. ArticleCASPubMed Google Scholar
Shin KH, Kim JM, Rho KS, Park KH, Oh JE, Min BM . (2002). Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas. Int J Oncol21: 997–1001. CASPubMed Google Scholar
Shmueli A, Oren M . (2004). Regulation of p53 by Mdm2: fate is in the numbers. Mol Cell13: 4–5. ArticleCASPubMed Google Scholar
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell95: 29–39. ArticleCASPubMed Google Scholar
Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW . (2000). High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/− mice. Cancer Res60: 3605–3611. CASPubMed Google Scholar
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet15: 356–362. ArticleCASPubMed Google Scholar
Strong LC, Williams WR, Tainsky MA . (1992). The Li–Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol135: 190–199. ArticleCASPubMed Google Scholar
Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J et al. (1999). PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA96: 6199–6204. ArticleCASPubMedPubMed Central Google Scholar
Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I et al. (1998). High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol8: 1169–1178. ArticleCASPubMed Google Scholar
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM . (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science280: 1614–1617. ArticleCASPubMed Google Scholar
Tang Y, Eng C . (2006). PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer Res66: 736–742. ArticleCASPubMed Google Scholar
Tlsty TD, White A, Livanos E, Sage M, Roelofs H, Briot A et al. (1994). Genomic integrity and the genetics of cancer. Cold Spring Harb Symp Quant Biol59: 265–275. ArticleCASPubMed Google Scholar
Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP . (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature441: 523–527. ArticleCASPubMedPubMed Central Google Scholar
Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H et al. (2007). Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell128: 141–156. ArticleCASPubMedPubMed Central Google Scholar
Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ et al. (2007). Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell11: 555–569. ArticleCASPubMed Google Scholar
Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D et al. (1997). Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res57: 4183–4186. CASPubMed Google Scholar
Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z et al. (2007). NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell128: 129–139. ArticleCASPubMedPubMed Central Google Scholar
Weinberg RA . (1992). The retinoblastoma gene and gene product. Cancer Surv12: 43–57. CASPubMed Google Scholar
Weng L, Brown J, Eng C . (2001a). PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet10: 237–242. ArticleCASPubMed Google Scholar
Weng LP, Brown JL, Baker KM, Ostrowski MC, Eng C . (2002). PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway. Hum Mol Genet11: 1687–1696. ArticleCASPubMed Google Scholar
Weng LP, Smith WM, Brown JL, Eng C . (2001b). PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet10: 605–616. ArticleCASPubMed Google Scholar
Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C . (2002). Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer99: 63–67. ArticleCASPubMed Google Scholar
Woiwode A, Johnson SA, Zhong S, Zhang C, Roeder RG, Teichmann M et al. (2008). PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex. Mol Cell Biol28: 4204–4214. ArticleCASPubMedPubMed Central Google Scholar
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D . (1993). p21 is a universal inhibitor of cyclin kinases. Nature366: 701–704. ArticleCASPubMed Google Scholar
Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM . (1992). Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell70: 937–948. ArticleCASPubMed Google Scholar
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M . (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature352: 345–347. ArticleCASPubMed Google Scholar